Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07423546 | A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia | PHASE1 | NOT YET_RECRUITING | 12 | — | — | Jul 1, 2026 | Dec 31, 2027 | Apr 13, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Xanomeline 50 mg and trospium chloride 20mg (KarXT) | EXPERIMENTAL | 5 weeks of xanomeline 50mg/trospium 20mg bid (low dose arm). |
| Xanomeline 100 mg and trospium chloride 20mg (KarXT) | EXPERIMENTAL | 5 weeks of xanomeline 100mg/trospium 20mg bid (middle dose arm). |
| Xanomeline 125 mg and trospium chloride 30mg (KarXT) | EXPERIMENTAL | 5 weeks of xanomeline 125mg/trospium 30mg bid (high dose arm). |
| Name | Type | Description |
|---|---|---|
| Xanomeline and trospium chloride (KarXT) | DRUG | Subjects will be randomized to 5 weeks of low, middle, or high dose of Xanomeline and trospium chloride, and will complete a PET scan with \[18\]F DOPA at the beginning and end of the treatment period. |
Inclusion Criteria: 1. Individuals aged 18 to 50, inclusive at screen 2. Capable of understanding the study procedures and able to provide informed consent 3. Diagnosed with schizophrenia, schizoaffective, or schizophreniform disorder 4. Antipsychotic free at Visit 1 (by choice and for reasons unre...